Treating Diabetic Macular Edema with Faricimab
Author Information
Author(s): Muacevic Alexander, Adler John R, Al-Rufayie Moussa, Palmieri Filomena, Hamoud Bedan Aseel, Younis Saad, Ali Ahmad, Kurumthottical Mathew, Taechameekietichai Teerajet, Fabozzi Lorenzo
Primary Institution: Western Eye Hospital, Imperial College Healthcare NHS Trust, London, GBR
Hypothesis
Does faricimab improve visual and anatomical outcomes in patients with diabetic macular edema?
Conclusion
Faricimab significantly improves visual and anatomical outcomes in patients with diabetic macular edema.
Supporting Evidence
- Treatment-naïve patients showed significant improvement in BCVA from 0.86 to 0.23 Log MAR.
- CST reduced from 385.71 to 299.14 μm in treatment-naïve patients.
- Previously treated patients also demonstrated improvements in BCVA and CST.
- Few adverse events were noted, affirming the safety profile of faricimab.
- The study aligns with findings from the YOSEMITE and RHINE phase III clinical trials.
Takeaway
This study shows that a new treatment called faricimab helps people with diabetes see better and reduces swelling in their eyes.
Methodology
This retrospective study analyzed data from patients diagnosed with diabetic macular edema who received intravitreal faricimab injections over six months.
Potential Biases
Selection bias may be present due to reliance on existing medical records.
Limitations
The study is retrospective, has a small sample size, and a single-center design, which may limit the generalizability of the findings.
Participant Demographics
The mean age of participants was 62.28 years, with 60% male and 40% female; 88.33% had type 2 diabetes.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website